#United States #Rosemont #American Academy of Orthopaedic Surgeons #Ankle Osteoarthritis #Clinical Practice Guidelines

Overview of New Guidelines

On July 2, 2026, the American Academy of Orthopaedic Surgeons (AAOS) announced the release of its new Clinical Practice Guideline (CPG) focusing on the management of ankle osteoarthritis (OA). This marks a significant advancement in orthopaedic care, as it’s the first guideline dedicated specifically to this condition, which predominantly affects a younger, active demographic.

The Significance of the Guideline

Traditionally, osteoarthritis has been associated with older populations, particularly affecting the hips and knees. However, ankle OA presents a unique challenge due to its prevalence among working-age individuals, which can hinder mobility and quality of life. Dr. Christopher Gross, co-chair of the CPG workgroup, highlighted the importance of recognizing ankle OA as a distinct clinical issue worthy of specialized attention. He stated, "Unlike hip and knee OA, ankle OA has its unique challenges, and it's crucial that we establish specific guidelines to address them."

Current Recommendations on Treatment Options

The new CPG emphasizes evidence-based treatment options for ankle OA, encompassing both surgical and non-surgical interventions. It offers two primary recommendations:
1. A moderate recommendation against the use of intra-articular platelet-rich plasma (PRP) for treating symptomatic ankle OA.
2. A strong recommendation against the use of intra-articular hyaluronic acid (HA) as a standalone treatment for the condition, while recognizing the potential short-term benefits when combined with corticosteroids.

Dr. Gross acknowledged his long-standing support for biologic treatments like PRP but noted a lack of robust evidence supporting its superiority over saline injections for pain relief. Additionally, access to HA therapy is often limited by insurance coverage, which poses another barrier for patients seeking treatment.

Insights on Treatment Efficacy

The guideline presents 11 consensus recommendations alongside a limited-strength option that surfaces when research is insufficient. Some notable consensus highlights include:

• - Short-term relief through intra-articular corticosteroid injections.
• - Skepticism regarding the efficacy of intra-articular stem cell therapy.
• - Mild to moderate symptomatic ankle OA patients may benefit from skilled physical therapy, which can enhance patient-reported outcomes and possibly alter the disease's progression.
• - Physical therapy can help restore motion, strength, and gait for postoperative patients.
• - Opioids are discouraged, while NSAIDs and acetaminophen may be utilized for initial relief contingent on the patient's medical history.
• - Encouragement of weight reduction as a means to improve symptoms and outcomes.

The guideline thus aims to equip patients and healthcare providers with better insights for shared decision-making, ultimately enhancing patient care in managing ankle OA.

Future Directions

While the CPG lays down a foundation for managing symptomatic ankle OA, its authors hope to see additional guidelines focusing more on definitive surgical treatments in the future. Dr. Jeannie Huh, co-chair of the CPG workgroup, expressed optimism that these guidelines will lead to a broader understanding of treatment options available to patients while promoting dialogue between patients and orthopedic surgeons concerning the benefits and drawbacks of various procedures.

Through these guidelines, the AAOS strives to enhance the overall management of ankle osteoarthritis, ensuring that healthcare professionals and patients alike can navigate the complexities of treatment pathways effectively.

The full guidelines can be accessed through the AAOS's OrthoGuidelines website and mobile app, acting as a resource for ongoing education and best practices in orthopaedic care.